ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy Manufacturing
Tuesday, April 08, 2025
ABEC, a global leader in engineering solutions and services for biotechnology manufacturing, has launched its Advanced Therapy Bioreactor (ATB™). This revolutionary platform has the potential to change the way cells for advanced therapy pharmaceuticals (ATMPs) are expanded. Designed to overcome the limitations of existing systems, the ATB™ provides unprecedented process control and scalability from laboratory to commercial scale.
ATB™ redefines cell culture by simulating the human circulatory system. Its proprietary hollow fiber membrane network enables local nutrient delivery and waste removal, ensuring that each cell is in optimal growth conditions. Unlike traditional systems that rely on bubbles and mechanical agitation, ATB™'s oscillation-based mixing and diffusion-based gas and nutrient/waste transport maintain an optimal cell growth environment for sensitive cell lines. The bioreactor and process flow path are disposable, and the system operation is closed and fully automated.
Designed for seamless scale-up, ATB™ also maintains a constant ratio between hollow fiber surface area and bioreactor volume at all scales (0.2L to 10L), allowing consistent cell culture conditions from early development to clinical and commercial production. In extensive testing, ATB™ has demonstrated high cell density and cell viability for primary T cells, CD34+ stem cells, and HEK293 and CHO cell lines.
“The launch of ATB™ is another milestone in ABEC’s 50-year history of bioprocessing innovation,” said Scott Pickering, CEO of ABEC. “Like the solutions we offer for recombinant protein production, ATB™ has the potential to solve the toughest challenges in advanced therapeutic manufacturing and accelerate our partners’ path to the clinic and market.”
About ABEC
Since 1974, ABEC has been a global leader in providing engineered process solutions and services for the manufacturing segment of the biotechnology industry. The majority of the world's pharmaceutical and biotechnology companies are ABEC customers, and many of today's leading therapies rely on processes and equipment designed, manufactured, installed and maintained by ABEC. ABEC's unique value comes from its extensive experience, complete in-house capabilities, customizable and flexible approach and long-standing reputation. Whether adding capacity or improving existing facilities, ABEC's turnkey solutions and support services help reduce overall costs, shorten time to market, and maximize production efficiency. To learn more about ABEC, visit abec.com , email info@abec.com , and follow us on LinkedIn .
Disclaimer: The original version of this announcement is the official authorized version. The translation is for convenience only. Please refer to the original text, which is the only version with legal effect.
Contacts
Media Contact: Rachel Peri, Marketing Coordinator, +1 (610) 861 4666,rperi@abec.com
Source: businesswire.com
